StockNews.com Downgrades Xencor (NASDAQ:XNCR) to Sell

StockNews.com downgraded shares of Xencor (NASDAQ:XNCR) from a hold rating to a sell rating in a research note issued to investors on Wednesday.

A number of other equities analysts have also weighed in on the stock. Wells Fargo & Company started coverage on shares of Xencor in a research report on Thursday, December 12th. They set an “overweight” rating and a $37.00 target price for the company. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. Wedbush reiterated an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. BMO Capital Markets restated an “outperform” rating and set a $34.00 price target (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. Finally, JPMorgan Chase & Co. increased their target price on Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.88.

Xencor Stock Down 0.5 %

NASDAQ XNCR opened at $14.38 on Wednesday. Xencor has a 12 month low of $14.18 and a 12 month high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.01 billion, a PE ratio of -4.49 and a beta of 0.70. The stock’s 50 day moving average is $19.98 and its 200 day moving average is $20.72.

Insider Activity at Xencor

In related news, Director Alan Bruce Montgomery sold 1,421 shares of Xencor stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $27.03, for a total transaction of $38,409.63. Following the completion of the transaction, the director now directly owns 9,140 shares of the company’s stock, valued at approximately $247,054.20. The trade was a 13.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.23% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of XNCR. Sterling Capital Management LLC lifted its stake in shares of Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,040 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Xencor during the fourth quarter worth $34,000. GAMMA Investing LLC boosted its stake in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 508 shares during the period. KBC Group NV grew its holdings in shares of Xencor by 63.5% in the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 1,213 shares during the last quarter. Finally, Quarry LP increased its stake in Xencor by 111.4% in the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 2,108 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.